Using deep learning to detect patients at risk for prostate cancer despite benign biopsies

Background: Transrectal ultrasound guided systematic biopsies of the prostate is a routine procedure to establish a prostate cancer diagnosis. However, the 10-12 prostate core biopsies only sample a relatively small volume of the prostate, and tumour lesions in regions between biopsy cores can be missed, leading to a well-known low sensitivity to detect clinically relevant cancer. As a proof-of-principle, we developed and validated a deep convolutional neural network model to distinguish between morphological patterns in benign prostate biopsy whole slide images from men with and without established cancer. Methods: This study included 14,354 hematoxylin and eosin stained whole slide images from benign prostate biopsies from 1,508 men in two groups: men without an established prostate cancer (PCa) diagnosis and men with at least one core biopsy diagnosed with PCa. 80% of the participants were assigned as training data and used for model optimization (1,211 men), and the remaining 20% (297 men) as a held-out test set used to evaluate model performance. An ensemble of 10 deep convolutional neural network models was optimized for classification of biopsies from men with and without established cancer. Hyperparameter optimization and model selection was performed by cross-validation in the training data . Results: Area under the receiver operating characteristic curve (ROC-AUC) was estimated as 0.727 (bootstrap 95% CI: 0.708-0.745) on biopsy level and 0.738 (bootstrap 95% CI: 0.682 - 0.796) on man level. At a specificity of 0.9 the model had an estimated sensitivity of 0.348. Conclusion: The developed model has the ability to detect men with risk of missed PCa due to under-sampling of the prostate. The proposed model has the potential to reduce the number of false negative cases in routine systematic prostate biopsies and to indicate men who could benefit from MRI-guided re-biopsy.

Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression based convolutional neural networks

Molecular phenotyping by gene expression profiling is common in contemporary cancer research and in molecular diagnostics. However, molecular profiling remains costly and resource intense to implement, and is just starting to be introduced into clinical diagnostics. Molecular changes, including genetic alterations and gene expression changes, occuring in tumors cause morphological changes in tissue, which can be observed on the microscopic level. The relationship between morphological patterns and some of the molecular phenotypes can be exploited to predict molecular phenotypes directly from routine haematoxylin and eosin (H&E) stained whole slide images (WSIs) using deep convolutional neural networks (CNNs). In this study, we propose a new, computationally efficient approach for disease specific modelling of relationships between morphology and gene expression, and we conducted the first transcriptome-wide analysis in prostate cancer, using CNNs to predict bulk RNA-sequencing estimates from WSIs of H&E stained tissue. The work is based on the TCGA PRAD study and includes both WSIs and RNA-seq data for 370 patients. Out of 15586 protein coding and sufficiently frequently expressed transcripts, 6618 had predicted expression significantly associated with RNA-seq estimates (FDR-adjusted p-value < 1*10-4) in a cross-validation. 5419 (81.9%) of these were subsequently validated in a held-out test set. We also demonstrate the ability to predict a prostate cancer specific cell cycle progression score directly from WSIs. These findings suggest that contemporary computer vision models offer an inexpensive and scalable solution for prediction of gene expression phenotypes directly from WSIs, providing opportunity for cost-effective large-scale research studies and molecular diagnostics.

Pathologist-Level Grading of Prostate Biopsies with Artificial Intelligence

Background: An increasing volume of prostate biopsies and a world-wide shortage of uro-pathologists puts a strain on pathology departments. Additionally, the high intra- and inter-observer variability in grading can result in over- and undertreatment of prostate cancer. Artificial intelligence (AI) methods may alleviate these problems by assisting pathologists to reduce workload and harmonize grading. Methods: We digitized 6,682 needle biopsies from 976 participants in the population based STHLM3 diagnostic study to train deep neural networks for assessing prostate biopsies. The networks were evaluated by predicting the presence, extent, and Gleason grade of malignant tissue for an independent test set comprising 1,631 biopsies from 245 men. We additionally evaluated grading performance on 87 biopsies individually graded by 23 experienced urological pathologists from the International Society of Urological Pathology. We assessed discriminatory performance by receiver operating characteristics (ROC) and tumor extent predictions by correlating predicted millimeter cancer length against measurements by the reporting pathologist. We quantified the concordance between grades assigned by the AI and the expert urological pathologists using Cohen's kappa. Results: The performance of the AI to detect and grade cancer in prostate needle biopsy samples was comparable to that of international experts in prostate pathology. The AI achieved an area under the ROC curve of 0.997 for distinguishing between benign and malignant biopsy cores, and 0.999 for distinguishing between men with or without prostate cancer. The correlation between millimeter cancer predicted by the AI and assigned by the reporting pathologist was 0.96. For assigning Gleason grades, the AI achieved an average pairwise kappa of 0.62. This was within the range of the corresponding values for the expert pathologists (0.60 to 0.73).